• 1 Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199, Tung Hwa North Road, Taipei, Taiwan.
  • 2 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  • 3 NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand
  • 4 Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
  • 5 Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan
  • 6 Graduate Institute of Clinical Medicine, Department of Internal Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  • 7 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
  • 8 Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, WHO Regional Reference Laboratory for Hepatitis B, Melbourne, Australia
  • 9 Department of Gastroenterology and Hepatology, National University Health Systems, Yong Loo Lin School of Medicine, Singapore, Singapore
  • 10 Department of Internal Medicine, Yonsei University College of Medicine, Liver Cirrhosis Clinical Research Center, Seoul, Korea
  • 11 Bombay Hospital and Medical Research Centre, Mumbai, India
  • 12 Royal Brisbane Hospital, University of Queensland, Brisbane, Australia
  • 13 Department of Medicine, Aga Khan University, Karachi, Pakistan
  • 14 University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 15 Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • 16 Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
  • 17 Department of Medicine, University of Indonesia, Jakarta, Indonesia
  • 18 University of Santo Tomas, España Blvd., Manila, Philippines
  • 19 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 20 Yamanashi-ken Hospital Organization, Central and Kita Hospitals, University of Tokyo, Tokyo, Japan
Hepatol Int, 2012 Jun;6(3):531-61.
PMID: 26201469 DOI: 10.1007/s12072-012-9365-4


Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.